NASDAQ: IBRX - ImmunityBio, Inc.

Yield per half year: -18.3%
Dividend yield: 0.00%
Sector: Healthcare

Share chart ImmunityBio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About ImmunityBio, Inc.

ImmunityBio, Inc., компания, занимающаяся иммунотерапией, разрабатывает вакцину против Т-клеточного рака памяти для борьбы с несколькими типами опухолей без использования высокодозной химиотерапии. Он разрабатывает химиотерапевтическую терапию, связанную с альбумином (альдоксорубицин), новый суперагонист цитокинов IL-15 (N-803), ингибиторы контрольных точек, поляризующие макрофаги пептиды, биспецифические гибридные белки, нацеленные на TGFb и IL-12, лечение аденовирусом и дрожжевой вакциной. нацеливание на ассоциированные с опухолью антигены и неоэпитопы. ImmunityBio, Inc.

more details
ранее была известна как NantCell, Inc. и сменила название на ImmunityBio, Inc. в июне 2019 года. Компания была зарегистрирована в 2014 году и находится в Эль-Сегундо, Калифорния. ImmunityBio, Inc. действует как дочерняя компания NantWorks, LLC.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-07-28
ISIN US45256X1037
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт http://immunitybio.com
Цена ао 2.93
Change price per day: +1.92% (2.87)
Change price per week: -2.17% (2.99)
Change price per month: -7.73% (3.17)
Change price per 3 month: -3.78% (3.04)
Change price per half year: -18.3% (3.58)
Change price per year: -40.43% (4.91)
Change price per 3 year: -51.57% (6.04)
Change price per 5 year: -42.31% (5.07)
Change price per 10 year: 0% (2.925)
Change price per year to date: +9.55% (2.67)
All parameters

Underestimation

Title Value Grade
P/S 3630.77 1
P/BV -3.85 0
P/E 0 0
EV/EBITDA -8.39 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -115.61 0
ROE, % 99.35 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -2.01 10
Total: 7.8

Growth impulse

Title Value Grade
Yield Revenue, % -68.9 0
Yield Ebitda, % 211.56 10
Yield EPS, % 179.66 10
Total: 8
More

Institutions Volume Share, %
Vanguard Group Inc 13328525 1.97
Blackrock Inc. 10710179 1.58
State Street Corporation 9470909 1.4
Geode Capital Management, LLC 3379464 0.5
Credit Suisse Ag/ 1529908 0.23
JP Morgan Chase & Company 1422212 0.21
Northern Trust Corporation 1357059 0.2
Goldman Sachs Group Inc 1278638 0.19
Charles Schwab Investment Management, Inc. 1142925 0.17
Bank of America Corporation 891815 0.13

ETFShare, %Profitability for 1 year, %Dividends, %
Amplify Treatments Testing and Advancements ETF 4.87 10.31 1.06
Future Tech ETF 0.23617 426.34 0.8416
Principal Healthcare Innovators ETF 0.23617 618.5 0.8416
iShares Russell 2000 Growth ETF 0.02882 38.04 0.6026
iShares Russell 3000 ETF 0.00114 24.83 1.43482
1.08223.60.95



Head Job title Payment Year of birth
Mr. David C. Sachs Chief Financial Officer 533.33k 1978 (47 years)
Mr. Richard Gerald Adcock President, CEO & Director 849.45k 1969 (56 years)
Ms. Sarah Singleton Chief Communications Officer & Head of Patient Advocacy N/A
Dr. Leonard S. Sender M.D. Chief Operating Officer N/A
Mr. Jason R. Liljestrom General Counsel & Corporate Secretary N/A 1983 (42 years)
Dr. Sandeep K. Reddy M.D. Chief Medical Officer N/A
Dr. Barry J. Simon M.D. Chief Corporate Affairs Officer & Director N/A 1965 (60 years)
Dr. Enrique Diloné Ph.D., RAC Chief Technology Officer N/A 1967 (58 years)
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. Executive Chairman of the Board and Global Chief Scientific & Medical Officer 629.19k 1953 (72 years)
Ms. Regan J. Lauer Chief Accounting Officer 1970 (55 years)

Address: United States, San Diego, CA , 3530 John Hopkins Court - open in Google maps, open in Yandex maps
Website: http://immunitybio.com